Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Drug Name | Ponatinib |
| Trade Name | Iclusig |
| Synonyms | AP24534 |
| Drug Descriptions |
Iclusig (ponatinib) inhibits the Bcr-Abl fusion, and other tyrosine kinases, such as RET, DDR, VEGFR, FGFR, KIT, and FLT3 (PMID: 23526464, PMID: 25284748, PMID: 19878872). Iclusig (ponatinib) is FDA approved for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL) as well as ABL1 T315I CML and ABL1 T315I Ph positive ALL (FDA.gov). |
| DrugClasses | ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 29 DDR1 Inhibitor 8 DDR2 inhibitor 7 FGFR Inhibitor (Pan) 24 FLT3 Inhibitor 61 KIT Inhibitor 55 PDGFR-alpha Inhibitor 10 RET Inhibitor 48 SRC Inhibitor 31 VEGFR Inhibitor (Pan) 33 |
| CAS Registry Number | 943319-70-8 |
| NCIT ID | C95777 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
CKB BOOST